Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial

Share Article

The Firm is representing numerous clients in Risperdal lawsuits that have been filed in the Pennsylvania mass tort proceeding, all of whom allegedly developed gynecomastia due to treatment with the atypical antipsychotic medication.

Free Case Review
We are pleased that this second bellwether trial has commenced, and look forward to its outcome, as it may provide further insight into how juries will react in similar Risperdal lawsuits.

Risperdal lawsuits (http://www.risperdallawsuit2014.com/) continue to move forward in a Pennsylvania mass tort litigation currently underway in the Philadelphia Court of Common Pleas, where a jury has begun hearing testimony in the proceeding’s second bellwether trial involving allegations that the atypical antipsychotic medication can cause gynecomastia, or male breast growth. According to court documents, the case in question was filed on behalf of a plaintiff who was prescribed Risperdal as a child to treat oppositional defiant disorder before the medication was approved for any pediatric indications. On March 4th, jurors heard testimony from a Janssen Pharmaceuticals marketing official who was questioned about the tactics used to promote Risperdal, as well as its off-label use in children. (Case No. 130301803)

“Our Firm is representing numerous plaintiffs who also allege they developed gynecomastia due to Risperdal. We are pleased that this second bellwether trial has commenced, and look forward to its outcome, as it may provide further insight into how juries will react in similar Risperdal lawsuits,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm continues to provide legal consultations to men and boys who allegedly developed gynecomastia, due to their use of Risperdal.

Risperdal Litigation
Risperdal is an atypical antipsychotic drug that is approved by the U.S. Food & Drug Administration (FDA) to treat adult and adolescent schizophrenia, bipolar disorder in adults and children ages 10-to-17, and irritability in children (5-to-16 years of age) with autistic disorder. While the drug came to market in the 1990s,its first pediatric indications were not approved until 2006.*

Court documents indicate that nearly 1,300 Risperdal claims have been filed in the Pennsylvania mass tort on behalf of individuals who allegedly suffered gynecomastia and other side effects due to their use of the medication. Like the case currently at trial, these claims accuse Janssen and its parent company, Johnson & Johnson, of concealing the drug’s serious side effects and failing to warn doctors and patients of these risks. The lawsuits also allege that the companies improperly promoted the use of Risperdal in children long before the FDA cleared the drug for such indications. (In Re: Risperdal Litigation, Case Number 100300296)

According to court records, the Pennsylvania litigation’s first bellwether trial involving Risperdal and gynecomastia concluded on February 24th, with the jury awarding $2.5 million to a man who was prescribed the medication off-label as a boy to treat autism. According to the complaint, the plaintiff developed size 44 DD breasts as a result of his treatment with Risperdal. (Case No. A-196444)

Risperdal patients who allegedly developed gynecomastia connected with its use may be entitled to compensation for medical bills, lost wages, emotional distress, pain and suffering, and more. To learn more about the ongoing Risperdal litigation, please contact Bernstein Liebhard LLP for a free case review by visiting the Firm’s website, or by calling 800-511-5092.

*fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108759.htm, FDA, October 6, 2006

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
info (at) consumerinjurylawyers (dot) com
http://www.risperdallawsuit2014.com/
https://plus.google.com/115936073311125306742?rel=author

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sandy A. Liebhard
Follow us on
Visit website